Evidence map›Paper›PMID 40672756›Full record

ReviewFrontiers in oncology2025

USP39: a key regulator in malignant tumor progression.

Junyan Li, Jinghua Zhong, Jianming Ye, Yi Xiang, Xiangcai Wang

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Junyan Li *The First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi, China.
Jinghua Zhong *The Oncology Department of the First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Jianming Ye *The Oncology Department of the First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Yi Xiang *The Oncology Department of the First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Xiangcai Wang *The Oncology Department of the First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ubiquitin-specific protease 39 (USP39), a member of the USP family, plays a unique role beyond classical deubiquitination by interacting with target molecules and regulating their pre-mRNA splicing, which enhances its functional specificity compared to other USP family members. Growing evidence highlights USP39's critical involvement in the progression of malignant tumors, where it acts as a pro-tumor factor, influencing cancer growth, proliferation, and metastasis. This paper provides a comprehensive review of the structure and functional mechanisms of USP39, emphasizing its role in regulating malignant tumor progression across various cancer types. Additionally, we explore the potential for developing targeted inhibitors based on USP39's regulatory functions, offering a theoretical framework for future drug development. Furthermore, the study examines USP39's contribution to resistance against antitumor therapies, highlighting its clinical relevance in advancing cancer treatment strategies. Despite the advances made, research on USP39-specific inhibitors remains limited. This work introduces a novel approach to designing inhibitors by leveraging USP39's functional and structural characteristics, paving the way for new therapeutic avenues in cancer research.

Indexed as

cancerdeubiquitinationmalignancypre-mRNA splicingUSP39

Identifiers

PMID40672756
PMCPMC12265305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.